Vivo Capital LLC Takes $8.86 Million Position in Silence Therapeutics plc (NASDAQ:SLN)

Vivo Capital LLC purchased a new stake in Silence Therapeutics plc (NASDAQ:SLN) during the fourth quarter, Holdings Channel reports. The firm purchased 510,204 shares of the company’s stock, valued at approximately $8,862,000. Silence Therapeutics makes up approximately 0.7% of Vivo Capital LLC’s portfolio, making the stock its 28th biggest position.

Separately, SG Americas Securities LLC acquired a new stake in Silence Therapeutics in the 4th quarter valued at $110,000. 98.73% of the stock is owned by institutional investors.

Silence Therapeutics Trading Up 1.2 %

NASDAQ:SLN traded up $0.27 on Thursday, reaching $22.87. 2,336 shares of the company’s stock were exchanged, compared to its average volume of 224,668. The business has a fifty day moving average of $22.67 and a 200-day moving average of $18.33. The company has a quick ratio of 4.56, a current ratio of 4.56 and a debt-to-equity ratio of 0.01. Silence Therapeutics plc has a 52-week low of $4.84 and a 52-week high of $27.72. The firm has a market capitalization of $684.50 million, a price-to-earnings ratio of -15.48 and a beta of 1.38.

Silence Therapeutics (NASDAQ:SLN) last released its earnings results on Wednesday, March 13th. The company reported ($0.47) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.22). Silence Therapeutics had a negative return on equity of 262.17% and a negative net margin of 171.41%. The firm had revenue of $2.61 million for the quarter, compared to analysts’ expectations of $11.46 million. As a group, analysts expect that Silence Therapeutics plc will post -1.38 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on SLN shares. Chardan Capital lifted their target price on shares of Silence Therapeutics from $26.00 to $42.00 and gave the stock a “buy” rating in a research note on Thursday, March 14th. HC Wainwright reaffirmed a “buy” rating and set a $75.00 target price on shares of Silence Therapeutics in a research note on Friday, March 15th. Morgan Stanley reissued an “overweight” rating and set a $45.00 price target on shares of Silence Therapeutics in a research report on Monday, April 22nd. Finally, BMO Capital Markets initiated coverage on shares of Silence Therapeutics in a report on Wednesday, January 31st. They issued an “outperform” rating and a $67.00 price objective on the stock.

Silence Therapeutics Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.